NCT07029971View on ClinicalTrials.gov

A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Ulcerative Colitis (UC)
Interventions
BIOLOGICAL

BB-TL1A-VIAL-HLE

Anti-TL1A monoclonal antibody

Trial Locations (2)

2000

RECRUITING

Dymocks Building, WellShare Site, Sydney

2102

RECRUITING

Arcadia Pittwater Private Hospital (Operated by Battery Bio), Warriewood

All Listed Sponsors
lead

Battery Bio Australia Pty Ltd

INDUSTRY